Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Schizophr Bull ; 48(1): 154-165, 2022 01 21.
Article in English | MEDLINE | ID: mdl-34313787

ABSTRACT

OBJECTIVES: Patients with psychiatric disorders have an increased risk of cardiovascular pathologies. A bidirectional feedback model between the brain and heart exists widely in both psychotic and nonpsychotic disorders. The aim of this study was to compare heart rate variability (HRV) and pulse wave velocity (PWV) functions between patients with psychotic and nonpsychotic disorders and to investigate whether subgroups defined by HRV and PWV features improve the transdiagnostic psychopathology of psychiatric classification. METHODS: In total, 3448 consecutive patients who visited psychiatric or psychological health services with psychotic (N = 1839) and nonpsychotic disorders (N = 1609) and were drug-free for at least 2 weeks were selected. HRV and PWV indicators were measured via finger photoplethysmography during a 5-minute period of rest. Canonical variates were generated through HRV and PWV indicators by canonical correlation analysis (CCA). RESULTS: All HRV indicators but none of the PWV indicators were significantly reduced in the psychotic group relative to those in the nonpsychotic group. After adjusting for age, gender, and body mass index, many indices of HRV were significantly reduced in the psychotic group compared with those in the nonpsychotic group. CCA analysis revealed 2 subgroups defined by distinct and relatively homogeneous patterns along HRV and PWV dimensions and comprising 19.0% (subgroup 1, n = 655) and 80.9% (subgroup 2, n = 2781) of the sample, each with distinctive features of HRV and PWV functions. CONCLUSIONS: HRV functions are significantly impaired among psychiatric patients, especially in those with psychosis. Our results highlight important subgroups of psychiatric patients that have distinct features of HRV and PWV which transcend current diagnostic boundaries.


Subject(s)
Autonomic Nervous System/physiopathology , Cardiovascular Diseases/physiopathology , Mental Disorders/physiopathology , Psychotic Disorders/physiopathology , Pulse Wave Analysis , Adult , Cardiovascular Diseases/epidemiology , Comorbidity , Female , Heart Rate/physiology , Humans , Male , Mental Disorders/epidemiology , Middle Aged , Plethysmography , Psychotic Disorders/epidemiology
2.
Eur Arch Psychiatry Clin Neurosci ; 268(1): 49-56, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28761988

ABSTRACT

Neurological soft signs (NSS) are one of the biomarkers for schizophrenia spectrum disorders. However, a few studies have examined the prevalence of NSS across the schizophrenia spectrum. The present study adopted a quasi-longitudinal study design and examined the prevalence of NSS and their associations with clinical and behavioural manifestations in participants in different stages of the illness. The abridged version of the Cambridge Neurological Inventory was administered to 39 patients with the first-episode schizophrenia, 39 individuals with ultra-high risk (UHR) for psychosis, 39 individuals with schizotypy, and 39 healthy controls. Patients with the first-episode schizophrenia had a higher prevalence of NSS in motor coordination than healthy controls as well as individuals with UHR and schizotypy. Individuals with UHR exhibited a higher prevalence of sensory integration items than individuals with schizotypy and healthy controls. Discriminant analysis classified the membership of the individuals correctly across the spectrum with an accuracy of up to 60.9%. In particular, NSS could discriminate individuals with UHR from healthy controls at up to 85.9% accuracy. These findings suggest that NSS are robust biomarkers to detect and discriminate individuals in different stages of the schizophrenia spectrum from healthy controls.


Subject(s)
Nervous System Diseases/etiology , Schizophrenia/diagnosis , Schizophrenia/physiopathology , Schizophrenic Psychology , Schizotypal Personality Disorder , Adolescent , Female , Humans , Longitudinal Studies , Male , Nervous System Diseases/diagnosis , Neurologic Examination , Neuropsychological Tests , Psychiatric Status Rating Scales , Schizotypal Personality Disorder/diagnosis , Schizotypal Personality Disorder/physiopathology , Schizotypal Personality Disorder/psychology , Statistics as Topic , Young Adult
3.
Neuropharmacology ; 108: 451-61, 2016 09.
Article in English | MEDLINE | ID: mdl-26603138

ABSTRACT

To study the cellular mechanism of vascular endothelial growth factor (VEGF)-enhanced neurogenesis in ischemic brain injury, we used middle cerebral artery occlusion (MCAO) model to induce transient focal ischemic brain injury. The results showed that ischemic injury significantly increased glial fibrillary acidic protein immunopositive (GFAP(+)) and nestin(+) cells in ipsilateral striatum 3 days following MCAO. Most GFAP(+) cells colocalized with nestin (GFAP(+)-nestin(+)), Pax6 (GFAP(+)-Pax6(+)), or Olig2 (GFAP(+)-Olig2(+)). VEGF further increased GFAP(+)-nestin(+) and GFAP(+)-Pax6(+) cells, and decreased GFAP(+)-Olig2(+) cells. We used striatal injection of GFAP targeted enhanced green fluorescence protein (pGfa2-EGFP) vectors combined with multiple immunofluorescent staining to trace the neural fates of EGFP-expressing (GFP(+)) reactive astrocytes. The results showed that MCAO-induced striatal reactive astrocytes differentiated into neural stem cells (GFP(+)-nestin(+) cells) at 3 days after MCAO, immature (GFP(+)-Tuj-1(+) cells) at 1 week and mature neurons (GFP(+)-MAP-2(+) or GFP(+)-NeuN(+) cells) at 2 weeks. VEGF increased GFP(+)-NeuN(+) and BrdU(+)-MAP-2(+) newborn neurons after MCAO. Fluorocitrate, an astrocytic inhibitor, significantly decreased GFAP and nestin expression in ischemic brains, and also reduced VEGF-enhanced neurogenic effects. This study is the first time to report that VEGF-mediated increase of newly generated neurons is dependent on the presence of reactive astrocytes. The results also illustrate cellular mechanism of VEGF-enhanced neural repair and functional plasticity in the brains after ischemic injury. We concluded that neurogenic effect of VEGF is related to increase of striatal astrocytes transdifferentiation into new mature neurons, which should be very important for the reconstruction of neurovascular units/networks in non-neurogenic regions of the mammalian brain.


Subject(s)
Astrocytes/physiology , Brain/physiology , Cell Transdifferentiation/physiology , Neurogenesis/physiology , Stroke/pathology , Vascular Endothelial Growth Factor A/administration & dosage , Animals , Astrocytes/drug effects , Brain/cytology , Brain/drug effects , Cell Transdifferentiation/drug effects , Injections, Intraventricular , Male , Neurogenesis/drug effects , Neurons/drug effects , Neurons/physiology , Rats , Rats, Sprague-Dawley , Stroke/drug therapy , Treatment Outcome
4.
Neurochem Int ; 55(7): 629-36, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19540294

ABSTRACT

To study the effect of VEGF overexpression on development of cortical newborn neurons in the brains after stroke, we injected human VEGF(165)-expressive plasmids (phVEGF) into the lateral ventricle of rat brains with a transient middle cerebral artery occlusion (MCAO). An injection of phVEGF significantly promoted angiogenesis (BrdU(+)-von Willebrand's factor(+)) and reduced infarct volume in the rat brain after MCAO. Single labeling of 5'-bromodeoxyuridine (BrdU) and double staining of BrdU with lineage-specific neuronal markers were used to indicate the proliferated cells and maturation of newborn neurons in the brain section of rats at 2, 4, and 8 weeks after MCAO. The results showed that BrdU positive (BrdU(+)) cells existed in ipsilateral frontal cortex within 8 weeks after MCAO and reached the maximum at 2 weeks of reperfusion. The phVEGF treatment significantly increased BrdU(+) cells compared with the control plasmid (pEGFP) injection. Cortical neurogenesis was indicated by the presence of newborn immature (BrdU(+)-Tuj1(+)), newborn mature (BrdU(+)-MAP-2(+)), and newborn GABAergic (BrdU(+)-GAD67(+)) neurons. All these neurons declined within 8 weeks after MCAO in the controls. Injection of phVEGF significantly increased BrdU(+)-Tuj1(+) neurons at 2 weeks, and BrdU(+)-MAP-2(+) neurons and BrdU(+)-GAD67(+) neurons at 4 and 8 weeks, respectively after MCAO. Moreover, phVEGF treatment significantly increased neurite length and branch numbers of BrdU(+)-MAP-2(+) newborn neurons compared with pEGFP treatment. These results demonstrate that VEGF enhances maturation of stroke-induced cortical neurogenesis and dendritic formation of newborn neurons in adult mammalian brains.


Subject(s)
Brain Ischemia/pathology , Cerebral Cortex/cytology , Neurites/drug effects , Neurons/drug effects , Vascular Endothelial Growth Factor A/pharmacology , Animals , Animals, Newborn , Antimetabolites , Blotting, Western , Bromodeoxyuridine , Cell Line , Cerebral Cortex/drug effects , Cerebral Cortex/growth & development , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Infarction, Middle Cerebral Artery/pathology , Magnetic Resonance Imaging , Male , Microscopy, Confocal , Neurites/ultrastructure , Neurons/ultrastructure , Plasmids/genetics , Rats , Rats, Sprague-Dawley , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...